Beigene, Ltd. ((ONC)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BeiGene, Ltd. is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer. The study aims to evaluate the efficacy and safety of ociperlimab combined with tislelizumab versus pembrolizumab in adults with high PD-L1 expression and untreated advanced non-small cell lung cancer (NSCLC).
The study tests the combination of ociperlimab and tislelizumab, both monoclonal antibodies, against pembrolizumab, another monoclonal antibody. Ociperlimab and tislelizumab are intended to enhance immune response against cancer cells.
This interventional study is randomized with a parallel assignment model. It uses triple masking, meaning the participant, care provider, and investigator are unaware of the treatment allocations. The primary purpose is treatment-focused.
The study began on June 8, 2021, with an active, not recruiting status as of the last update on June 23, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact BeiGene’s stock performance and investor sentiment, especially if the results favor the new combination therapy. It could also influence the competitive landscape in the oncology sector, particularly against established treatments like pembrolizumab.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.